Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1842053

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1842053

Middle East Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Market Size & Trends:

The Middle East active pharmaceutical ingredient CDMO market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 11.64 billion by 2033, growing at a CAGR of 5.58% from 2025 to 2033. The market is driven by the growing prevalence of chronic diseases, a focus on generic and biosimilar drugs, and significant technological advancements. Supportive government policies, investment in pharmaceutical infrastructure, and streamlined regulatory processes further stimulate domestic and international players to expand operations in the region.

In addition, the shifting preference of pharmaceutical companies toward outsourcing complex manufacturing processes rather than investing heavily in in-house capabilities is also one of the factors contributing to the market growth. Outsourcing these activities helps pharmaceutical companies to focus more resources on innovation, clinical research, and market expansion. These factors reduce financial risks, shorten development timelines, and allow for faster scalability, which is particularly valuable in a region where healthcare demand is rising rapidly. Furthermore, global players are showing increasing interest in entering the Middle Eastern market due to its strategic geographic location, which offers access to both developed and emerging economies, making it an attractive hub for pharmaceutical trade and distribution.

Furthermore, increasing government initiatives aimed at strengthening local drug manufacturing to ensure regional supply security are also one of the factors fueling the market growth. Several countries in the region are prioritizing domestic production capabilities to reduce dependence on imports and improve access to essential medicines. This has opened opportunities for CDMOs that can provide advanced technologies and regulatory expertise to support local firms. In parallel, a growing number of collaborations and joint ventures between multinational pharmaceutical companies and regional players are accelerating knowledge transfer and boosting overall manufacturing capacity.

Middle East Active Pharmaceutical Ingredient CDMO Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and country:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Traditional Active Pharmaceutical Ingredient (Traditional API)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • Biologics
  • Synthesis Outlook (Revenue, USD Million, 2021 - 2033)
  • Synthetic
  • Biotech
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovative
  • Generics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular disease
  • Diabetes
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
Product Code: GVR-4-68040-752-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Middle East Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunities
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Supply Chain Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Middle East Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Middle East Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
  • 4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
    • 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • 4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Movement Analysis
  • 5.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Million)
  • 5.4. Synthetic
    • 5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biotech
    • 5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Middle East Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Middle East Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
  • 6.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
  • 6.4. Innovative
    • 6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Generics
    • 6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Middle East Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Middle East Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
  • 7.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Hormonal
    • 7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Glaucoma
    • 7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Cardiovascular disease
    • 7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Diabetes
    • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Movement Analysis
  • 8.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
  • 8.4. Clinical
    • 8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Commercial
    • 8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Middle East Active Pharmaceutical Ingredient CDMO Market: Country Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market Snapshot
  • 9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. Saudi Arabia
    • 9.4.1. Key Country Dynamics
    • 9.4.2. Competitive Scenario
    • 9.4.3. Regulatory Framework
    • 9.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. UAE
    • 9.5.1. Key Country Dynamics
    • 9.5.2. Competitive Scenario
    • 9.5.3. Regulatory Framework
    • 9.5.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Kuwait
    • 9.6.1. Key Country Dynamics
    • 9.6.2. Competitive Scenario
    • 9.6.3. Regulatory Framework
    • 9.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Oman
    • 9.7.1. Key Country Dynamics
    • 9.7.2. Competitive Scenario
    • 9.7.3. Regulatory Framework
    • 9.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Qatar
    • 9.8.1. Key Country Dynamics
    • 9.8.2. Competitive Scenario
    • 9.8.3. Regulatory Framework
    • 9.8.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Company Market Share Analysis, 2024
  • 10.3. Company Profiles
    • 10.3.1. Cambrex Corporation
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Product/Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Recipharm AB
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product/Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Thermo Fisher Scientific Inc.
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product/Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. CordenPharma International
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product/Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Samsung Biologics
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product/Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Lonza
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product/Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Catalent, Inc.
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product/Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Siegfried Holding AG
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product/Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Piramal Pharma Solutions
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product/Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Boehringer Ingelheim International GmbH
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product/Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
Product Code: GVR-4-68040-752-4

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 3 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 4 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 5 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 6 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 9 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 10 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 11 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 12 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 13 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 14 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 15 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 16 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 17 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 18 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 19 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 20 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 21 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 22 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 23 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 24 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 25 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 26 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 27 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 28 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)
  • Table 29 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)
  • Table 30 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 31 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Middle East Active Pharmaceutical Ingredient CDMO Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot 1
  • Fig. 13 Segment snapshot 2
  • Fig. 14 Segment snapshot 3
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 Middle East Active Pharmaceutical Ingredient CDMO Market dynamics
  • Fig. 19 Total R&D drug pipeline size, 2021 - 2024
  • Fig. 20 Total drug pipeline by development phase, 2024
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 PESTEL analysis
  • Fig. 23 Middle East Active Pharmaceutical Ingredient CDMO Market Product outlook: Segment dashboard
  • Fig. 24 Middle East Active Pharmaceutical Ingredient CDMO Market, by Product segment: Market share, 2025 & 2033
  • Fig. 25 Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Middle East Active Pharmaceutical Ingredient CDMO Market Synthesis outlook: Segment dashboard
  • Fig. 29 Middle East Active Pharmaceutical Ingredient CDMO Market, by Synthesis segment: Market share, 2025 & 2033
  • Fig. 30 Synthetic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Biotech market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Middle East Active Pharmaceutical Ingredient CDMO Market Drug outlook: Segment dashboard
  • Fig. 33 Middle East Active Pharmaceutical Ingredient CDMO Market, by Drug segment: Market share, 2025 & 2033
  • Fig. 34 Innovative market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Middle East Active Pharmaceutical Ingredient CDMO Market Application outlook: Segment dashboard
  • Fig. 37 Middle East Active Pharmaceutical Ingredient CDMO Market, by Application segment: Market share, 2025 & 2033
  • Fig. 38 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Hormonal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Glaucoma market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Middle East Active Pharmaceutical Ingredient CDMO Market Workflow outlook: Segment dashboard
  • Fig. 45 Middle East Active Pharmaceutical Ingredient CDMO Market, by Workflow segment: Market share, 2025 & 2033
  • Fig. 46 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Regional market: Key takeaways
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Middle East Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Kuwait Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UAE Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Oman Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Qatar Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Market participant categorization
  • Fig. 62 Heat map analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!